MADRID 9 May. (EUROPA PRESS) –
The Spanish Academy of Dermatology and Venereology (AEDV) has highlighted its National Melanoma Registry to promote research on the disease, as well as to contribute to its knowledge and treatment.
Thus, he explained that the main objectives of the Melanoma Registry are to describe the epidemiology of cutaneous melanoma in Spain, improve the characterization of risk factors for this disease, both individual and those related to variability in health care, and evaluate their relationship with the prognosis.
“To prevent melanoma, AEDV emphasizes the importance of avoiding solar burns and excessive sun exposure, especially in children and young people, especially during the central hours of the day. The use of proper clothing, sunglasses, solar photoprotectors and avoiding tanning cabins,” says Onofre Sanmartín, head of the Dermatology Service of the Valencian Institute of Oncology Foundation (ivo).
In line, the Academy has warned that the incidence of melanoma in Spain continues to rise. Thus, he recalled the cancer incidence data in Spain prepared by the Spanish Network of Cancer Registries (Redecan), which estimates that in 2025 9,400 new cases will be diagnosed, with an incidence in the population of 15 cases per 100,000 people a year. Of these, 5,072 correspond to women and 4,336 to men.
By age groups, the largest number of cases is presented in people over 65 (4,169 cases), followed by the group between 45 and 60 years (3,757 cases) and, finally, in children under 44 a total of 1,482 cases. It is a disease that causes 1,000 deaths a year in Spain.
Therefore, the AEDV emphasizes that the early detection of melanoma is “crucial” to improve survival and reduce the morbidity associated with its treatment. “Regular skin self -exploration and medical consultation to the dermatologist is promoted to any suspicious or changing injury,” he adds.
In addition, it indicates that it is also necessary to take into account the novelties of the treatments, which according to Rafael Botella, head of the Dermatology Service at the La Fe Valencia University Hospital and Executive President of the 52nd Congress and the Valencian Section of the AEDV, focus on the use of neoadjuvant treatments both of immunotherapy in melanoma and the squamous cutaneous carcinoma In basal cell carcinoma.
“With neoadjuvant treatment we refer to the administration of drugs to patients with tumors before surgical intervention. This allows a complete or partial disappearance of tumors, so that surgery can be unnecessary or easier. On the other hand, neoadjuvant treatment in the case of melanom Doctor ends.
